Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Intravesical Apaziquone as a Surgical Adjuvant in Participant Undergoing Transurethral Resection Bladder Tumor (TURBT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02563561
Recruitment Status : Terminated
First Posted : September 30, 2015
Results First Posted : September 27, 2021
Last Update Posted : September 27, 2021
Sponsor:
Information provided by (Responsible Party):
Spectrum Pharmaceuticals, Inc

Brief Summary:

This is a Phase 3, randomized, multicenter, multi-arm, placebo-controlled, double-blind study of apaziquone in participants with ≤4 non-muscle invasive bladder cancer (NMIBC), ≤3.5 centimeters (cm) in diameter, all of which must had been fully resected at TURBT.

In addition to Screening, participants underwent an assessment of urothelial carcinoma of the bladder via cystoscopy for clinically apparent tumor Ta, G1-G2.

Following TURBT on Day 1, eligible participants were randomized to one of three treatment arms in a 1:1:1 ratio.

Arm 1 : One dose of Apaziquone. Arm 2 : Two Doses of Apaziquone. Arm 3 : Placebo. Primary endpoint was to evaluate the Time to Recurrence with either a one instillation of 4 mg apaziquone or two instillations of 4 milligram (mg) apaziquone relative to placebo instillation following TURBT in a participant with NMIBC who received TURBT.


Condition or disease Intervention/treatment Phase
Bladder Cancer Drug: Apaziquone Other: Placebo Phase 3

Detailed Description:

This is a Phase 3, randomized, multicenter, multi-arm, placebo-controlled, double-blind study of apaziquone in participants with ≤4 non-muscle invasive bladder tumors, ≤3.5 cm in diameter, all of which must have been fully resected at TURBT.

In addition to Screening, participants underwent an assessment of urothelial carcinoma of the bladder via cystoscopy for clinically apparent tumor Ta, G1-G2.

Following TURBT on Day 1, eligible participants were randomized to one of three treatment arms in a 1:1:1 ratio :

Arm 1 : One Dose of Apaziquone:

  • Day 1: administration of 4 mg of apaziquone 60±30 minutes post-TURBT
  • Day 15 (±5 days): administration of placebo

Arm 2 : Two Doses of Apaziquone :

  • Day 1: administration of 4 mg of apaziquone 60±30 minutes post-TURBT
  • Day 15 (±5 days): administration of 4 mg of apaziquone

Arm 3: Placebo :

  • Day 1 : administration of placebo 60±30 minutes post-TURBT
  • Day 15 (±5 days) : administration of placebo

Once randomized, Day 1 study drug instillation occurred 60 ±30 minutes post TURBT. Participants returned on Day 15 (±5 days) for a second instillation unless their pathology results showed non Ta, G1-G2 histology; in the absence of local pathology results by the Day 15 visit, participants received a second instillation of study drug. All histology specimens were reviewed by a local pathology laboratory and all clinical treatment decisions and study analyses were based on the local pathology review. Participants whose pathology was other than Ta, G1-G2 were followed for safety at Day 35 (±5 days) from the last dose of study drug and then discontinued from the study.

Participants with pathology confirmed Ta, G1-G2 disease were followed according to the schedule below :

  • Cystoscopic examination and urine cytology every 90 days (±10 days) (calculated from date of TURBT) through 24 months for tumor recurrence and progression.
  • If at any time during the 24 months follow up period there was a tumor recurrence, the participant continued on study with follow-up cystoscopic examination and urine cytology every 90 days (±10 days) (calculated from date of TURBT) through the end of 24 months. Participants with a recurrence were permitted to have a follow-up TURBT.
  • If at any time during the 24 months follow up period there was a tumor recurrence and/or participant started on another therapy, the participant was followed by telephone, for safety every 90 days (±10 days) (calculated from date of TURBT) through the end of 24 months.

Duration of Study: The duration of the study for each participant was approximately 24 months including:

  • Screening Period : 30-days
  • Treatment Period : Day 1 and Day 15 (±5 days)
  • Safety and Follow-up Period: 24-months

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 62 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Multicenter, Multi-Arm, Randomized, Multi-Dose, Placebo-Controlled, Double-Blind, Phase 3 Study of Intravesical Apaziquone (EOquin®) as a Surgical Adjuvant in the Immediate Postoperative Period in Patients Undergoing Transurethral Resection for Non- Muscle Invasive Bladder Cancer
Actual Study Start Date : October 9, 2015
Actual Primary Completion Date : March 10, 2017
Actual Study Completion Date : March 10, 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Bladder Cancer

Arm Intervention/treatment
Experimental: 1 Dose Apaziquone
Participants were randomized to receive first dose of 4 mg of apaziquone by intravesical administration into the bladder at 60 ± 30 minutes post transurethral resection of bladder tumor (TURBT) on Day 1 via an indwelling 100% Silicone Foley catheter. Followed by second dose of placebo by intravesical administration via an indwelling catheter on Day 15 (±5 days).
Drug: Apaziquone
One dose of apaziquone administered by intravesical administration
Other Name: EOquin

Other: Placebo
Matching placebo (containing 12 mg FD&C red #40, 15 mg sodium chloride, and 10 mg mannitol was supplied in identical appearing vials) by intravesical administration.

Experimental: 2 Dose Apaziquone
Participants were randomized to receive first dose of 4 mg of apaziquone by intravesical administration into the bladder at 60 ± 30 minutes post TURBT on Day 1 via an indwelling 100% Silicone Foley catheter. Followed by second dose of 4 mg of apaziquone by intravesical administration via an indwelling catheter on Day 15 (±5 days).
Drug: Apaziquone
One dose of apaziquone administered by intravesical administration
Other Name: EOquin

Placebo Comparator: Placebo
Participants were randomized to receive first dose of matching placebo by intravesical administration into the bladder at 60 ± 30 minutes post TURBT on Day 1 via an indwelling 100% Silicone Foley catheter. Followed by second dose of matching placebo by intravesical administration via an indwelling catheter on Day 15 (±5 days).
Other: Placebo
Matching placebo (containing 12 mg FD&C red #40, 15 mg sodium chloride, and 10 mg mannitol was supplied in identical appearing vials) by intravesical administration.




Primary Outcome Measures :
  1. Time to Recurrence [ Time Frame: From randomization to the date of first histologically confirmed recurrence of bladder cancer (up to 1.5 years) ]
    Time from randomization to the date of histologically confirmed recurrence of bladder cancer. A recurrence was defined as any pathologically confirmed disease of ≥Ta tumor histology or carcinoma in situ (CIS) post-treatment.


Secondary Outcome Measures :
  1. 2-Year Recurrence Rate [ Time Frame: 2 years ]
    The percentage of participants with histologically confirmed recurrence of the bladder tumor at any time after randomization and on or before Year 2. A recurrence was defined as any pathologically confirmed disease of ≥Ta tumor histology or CIS post-treatment.

  2. 1-Year Recurrence Rate [ Time Frame: 1 year ]
    The percentage of participants with histologically confirmed recurrence of the bladder tumor at any time after randomization and on or before Year 1. A recurrence was defined as any pathologically confirmed disease of ≥Ta tumor histology or CIS post-treatment.

  3. Time to Progression [ Time Frame: From randomization to the date of first disease progression (up to 1.5 years) ]
    Time to disease progression was defined as the time from randomization to the first disease progression. The development of T2 or greater disease was only included in the assessment of time to disease progression.

  4. Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Related Adverse Events, Serious Adverse Events (SAEs), TEAEs Leading to Discontinuation and Death [ Time Frame: Up to 1.5 Years ]
    An adverse event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it did not necessarily have to have a causal relationship with this treatment. TEAEs were adverse events that occurred from the first dose of study treatment until 40 days after the last dose of study drug administration or 40 days after the date of participant early discontinuation. Treatment-related AEs included TEAEs with relationship to study treatment reported as possible, probable, definite, or missing. An SAE was an AE resulting in any of the outcomes: death; initial/prolonged inpatient hospitalization; life-threatening experience; persistent or significant disability/incapacity; congenital anomaly.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria
  1. Participant must have had a diagnosis with urothelial carcinoma of the bladder with clinically apparent tumor Ta, G1-G2.
  2. Participant had ≤4 tumors, none of which exceeded 3.5 cm in diameter.
  3. Participant must have been willing to give written informed consent, able to adhere to dosing and visit schedules, and meet all study requirements.
  4. Participant was at least 18 years of age at randomization.
  5. Participant must have been willing to practice two forms of contraception, one of which must have been a barrier method, from study entry until at least 35 days after the last dose of the study drug.
  6. Female participant of childbearing potential must have had a negative pregnancy test within 30 days prior to randomization. Female participant who was postmenopausal for at least 1 year (defined as more than 12 months since last menses) or were surgically sterilized did not require this test.

Exclusion Criteria:

  1. Participant had an active concurrent malignancy/life-threatening disease. If there was a history of prior malignancies/life-threatening diseases, the participant was to be disease-free for at least 5 years. Participant with other prior malignancies less than 5 years before study entry could have still been enrolled if they had received treatment resulting in complete resolution of the cancer and currently had no clinical, radiologic, or laboratory evidence of active or recurrent disease.
  2. Participant had positive urine cytology for malignancy at Screening.
  3. Participant had an active uncontrolled infection, including a urinary tract infection, underlying medical condition, or other serious illness that would impair the ability of the participant to receive protocol treatment.
  4. Participant had used any investigational drugs, biologics, or devices within 30 days prior to study treatment or planned to use any of these during the course of the study.
  5. Participant had any prior intravesical chemotherapy, immunotherapy, or previous exposure to apaziquone.
  6. Participant had or has ever had

    • Upper tract Transitional Cell Carcinoma (TCC).
    • Urethral tumor (prostatic urethra included).
    • Any invasive bladder tumor known to be other than tumor Ta, G1-G2.
    • Any evidence of lymph node or distant metastasis.
    • Any bladder tumor with histology other than TCC.
    • Carcinoma in situ (CIS).
  7. Participant had a tumor in a bladder diverticulum.
  8. Participant had received any pelvic radiotherapy (including external beam and/or brachytherapy.)
  9. Participant had a bleeding disorder or a screening platelet count <100×10^9/L.
  10. Participant had screening hemoglobin <10 milligrams per deciliter (mg/dL).
  11. Participant had any unstable medical condition that would make it unsafe to undergo TURBT.
  12. Participant had a history of interstitial cystitis.
  13. Participant had a history of allergy to red color food dye.
  14. For a participant with a recurrent tumor, the participant had at least a 6-month cystoscopically-confirmed tumor-free interval between the last tumor recurrence and screening cystoscopic examination.
  15. Participant was pregnant or breast-feeding.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02563561


Locations
Layout table for location information
United States, Colorado
The Urology Center of Colorado
Denver, Colorado, United States, 80211
Sponsors and Collaborators
Spectrum Pharmaceuticals, Inc
  Study Documents (Full-Text)

Documents provided by Spectrum Pharmaceuticals, Inc:
Study Protocol  [PDF] August 6, 2015
Statistical Analysis Plan  [PDF] August 6, 2015

Layout table for additonal information
Responsible Party: Spectrum Pharmaceuticals, Inc
ClinicalTrials.gov Identifier: NCT02563561    
Other Study ID Numbers: SPI-EOQ-13-305
First Posted: September 30, 2015    Key Record Dates
Results First Posted: September 27, 2021
Last Update Posted: September 27, 2021
Last Verified: August 2021
Keywords provided by Spectrum Pharmaceuticals, Inc:
Bladder Cancer
Non-muscle invasive bladder cancer
Apaziquone
TURBT
Stage Ta, G1-G2
Additional relevant MeSH terms:
Layout table for MeSH terms
Urinary Bladder Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Urinary Bladder Diseases
Urologic Diseases
Apaziquone
Antineoplastic Agents